Cytiva and Pall Corporation investing 1.5 billion USD over two years to meet growing demand for biotechnology solutions

Rhea-AI Summary

Danaher Corporation (NYSE: DHR) announced a significant investment plan from its subsidiaries, Cytiva and Pall Corporation, totaling 1.5 billion USD over the next two years. This investment will enhance manufacturing capacity for key products used in biologic medicines across multiple geographies, including the US, UK, Austria, China, and other regions. Specific allocations include 600 million USD for chromatography resins, 400 million USD for cell culture media, and 300 million USD for single-use technologies. The initiative aims to address supply chain challenges and improve overall manufacturing agility.

Positive

• Investment of 1.5 billion USD will enhance production capabilities.
• 600 million USD allocated for new chromatography resin manufacturing site in the US.
• Expansion of cell culture media operations with 400 million USD investment.
• 300 million USD earmarked for single-use technologies, including new facilities in the UK and Cardiff.

Negative

• None.

AMERSHAM, United Kingdom, July 27, 2021 /PRNewswire/ -- An ongoing strategic growth plan from Cytiva and Pall Corporation, part of the Danaher (NYSE: DHR) Corporation, will expand manufacturing capacity and services across geographies for global life sciences customers.

The investment, already underway, includes new sites, expansion at existing factories, and is additional to previously announced investments.  It follows five acquisitions made by the companies so far this year.

Emmanuel Ligner, Danaher Group Executive, says: "Our customers tell us they need access to manufacturing agility, a robust global supply chain and more regional options. This investment further fuels our expansion program so we can rapidly meet the current and future needs of our customers and ultimately, their patients."

Cytiva and Pall Corporation's capacity expansion will increase the manufacture of key products used to make biologic medicines.

The companies are investing:

• 600+ million USD in chromatography resins – media for analyzing or purifying biomolecules – establishing a new manufacturing site in the US.
• 400+ million USD in cell culture media – in liquid or powder form this is used to grow and cultivate cells before they are purified– expand operations in the US, UK, and Austria.
• 300+ million USD in single-use technologies – including bioreactor bags for growing cells used to make personalized medicines and syringe filters for scientific research – expand operations in the US and the UK, as well as fitting out a new facility in Cardiff, Wales.
• 200+ million USD for continuing expansion work in Cytiva and Pall Corporation's sites across China and the rest of the Asia-Pacific region, Europe, and the US.

This investment also addresses some of the key challenges highlighted in the Global Biopharma Resilience Index, conducted by Longitude, a Financial Times company, and published by Cytiva in March 2021. These include hiring and training talent, R&D collaboration, supply chain resilience, manufacturing models, as well as government policy and regulation.

About Pall
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Part of the Danaher (NYSE: DHR) family of science and technology innovators, Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information visit www.pall.com.

About Cytiva
Cytiva is a global life sciences leader with more than 8,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. Part of the Danaher (NYSE: DHR) family of science and technology innovators, Cytiva is a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. For more information visit www.cytiva.com.

View original content:https://www.prnewswire.com/news-releases/cytiva-and-pall-corporation-investing-1-5-billion-usd-over-two-years-to-meet-growing-demand-for-biotechnology-solutions-301341492.html

SOURCE Cytiva

FAQ

What is Danaher Corporation investing in with the symbol DHR?

Danaher Corporation is investing 1.5 billion USD in its subsidiaries Cytiva and Pall Corporation to enhance manufacturing capacity for biotechnology solutions.

How much is Danaher investing in chromatography resins?

Danaher is investing over 600 million USD to establish a new manufacturing site for chromatography resins in the US.

What are the key areas of investment by Danaher for biotechnology solutions?

Key areas of investment include chromatography resins, cell culture media, and single-use technologies.

When did Danaher announce their investment plan for biotechnology solutions?

Danaher announced the investment plan on July 27, 2021.